Agios Pharmaceuticals Inc (AGIO)
31.49
-0.18
(-0.57%)
USD |
NASDAQ |
Apr 26, 15:17
Agios Pharmaceuticals Cash from Financing (TTM): 5.433M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 5.433M |
September 30, 2023 | 4.608M |
June 30, 2023 | 3.913M |
March 31, 2023 | 3.609M |
December 31, 2022 | 2.35M |
September 30, 2022 | -16.26M |
June 30, 2022 | -268.43M |
March 31, 2022 | -771.82M |
December 31, 2021 | -765.77M |
September 30, 2021 | -746.60M |
June 30, 2021 | -492.17M |
March 31, 2021 | 263.39M |
December 31, 2020 | 261.52M |
September 30, 2020 | 538.54M |
June 30, 2020 | 538.43M |
March 31, 2020 | 290.14M |
December 31, 2019 | 289.61M |
September 30, 2019 | 13.02M |
June 30, 2019 | 16.91M |
March 31, 2019 | 22.61M |
December 31, 2018 | 546.02M |
September 30, 2018 | 547.60M |
June 30, 2018 | 545.70M |
Date | Value |
---|---|
March 31, 2018 | 809.34M |
December 31, 2017 | 285.11M |
September 30, 2017 | 286.51M |
June 30, 2017 | 444.42M |
March 31, 2017 | 172.72M |
December 31, 2016 | 169.78M |
September 30, 2016 | 167.07M |
June 30, 2016 | 6.017M |
March 31, 2016 | 5.659M |
December 31, 2015 | 6.373M |
September 30, 2015 | 244.14M |
June 30, 2015 | 242.34M |
March 31, 2015 | 336.40M |
December 31, 2014 | 335.16M |
September 30, 2014 | 95.68M |
June 30, 2014 | 219.54M |
March 31, 2014 | 124.44M |
December 31, 2013 | 123.88M |
September 30, 2013 | 124.36M |
June 30, 2013 | 0.16M |
March 31, 2013 | 0.129M |
December 31, 2012 | 0.142M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-771.82M
Minimum
Mar 2022
538.54M
Maximum
Sep 2020
-43.66M
Average
4.608M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
Alnylam Pharmaceuticals Inc | 172.13M |
Blueprint Medicines Corp | 119.22M |
Corcept Therapeutics Inc | -148.72M |
Ionis Pharmaceuticals Inc | 644.08M |
Madrigal Pharmaceuticals Inc | 595.12M |